HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stability Data Reporting Section In FDA Draft Report Will Be Amended

This article was originally published in The Tan Sheet

Executive Summary

FDA will change the stability data reporting section of its June 1998 draft stability guidance to address comments to the agency following the draft's release, Center for Drug Evaluation & Research Stability Coordinating Committee Chairman Robert Seevers, PhD, said at an industry/FDA "Stability Testing and Control" meeting in East Rutherford, N.J. June 28.

You may also be interested in...



Stability testing and control

Workshops addressing avoidance of stability issues in the development of drug products, sponsored by CHPA, FDA, USP and other bodies, will be held in New Jersey June 28, Puerto Rico July 19, Missouri Aug. 2 and California Aug. 16. Objectives for the workshops include a review of the FDA draft guidance on stability released in June 1998, methods for establishing expiration dates and ensuring methods are stability indicating

Labeled Storage Statements On OTCs Opposed By NDMA

Labeled storage statements should not be applied to products marketed to consumers, and this exemption should be stated specifically in FDA's revised guidance for industry on drug stability testing, the Nonprescription Drug Manufacturers Association urges in Dec. 7 comments to the agency.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

RS140620

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel